Amgen AMGN · Forecast & Analysis
- A real-world study released November 5 showed Repatha cut heart attack risk by 20% versus ezetimibe in over 500,000 adults, the fresh driver behind the strongly bullish read.
- September's sharp drop, when Amgen lost roughly 10% after Novartis's pelacarsen failure, has stabilized, and the narrative has swung back toward the company's own strengths.
- The bullish case rests almost entirely on news and fundamentals right now; no fresh technical signals are in play, so conviction is moderate rather than extreme.
- The unresolved olpasiran readout remains a binary catalyst overhanging the shares until Amgen reports its own Lp(a) data.
News situation · 1 items / 30 D
1 of 1 straight from the issuer or regulator
Outlook for Amgen
Direction, typical moves and upcoming dates from our own price, news and calendar data, recalculated on every visit. An assessment, not investment advice.
What drives it
- The November 5 real-world study showing Repatha cut heart attack risk by 20% versus ezetimibe strengthens the cardiovascular franchise case.
- Positioning as a defensive equity with a growing pipeline and dividend, a profile that has historically held up better in market downturns.
- A top holding in the PBE healthcare ETF anchors long-term institutional demand.
- Stabilization after the September selloff suggests the event-driven damage has been absorbed.
What argues against it
- The olpasiran readout is unresolved; Amgen's own Lp(a) data is the key binary catalyst for a re-rating.
- Real-world evidence may persuade prescribers less than randomized trial data, and the Repatha release carried no financial guidance.
- A break below the post-selloff base near the September lows would reopen the risk of a full repeat of the 10% drawdown.
- High-impact US releases land shortly, including nonfarm payrolls and unemployment data within a day and CPI in about four days, a source of macro event risk.
Coming up
- US: Jobless claims
- US: EIA Crude Oil Stocks Change
- US: Producer prices · expected 0.4%, previous 0.7%
Economic data for AMGN
Full calendarRecently released
- November 10, 2026USDCore CPI y/y●●●Forecast 2.8%Previous 2.6%
- November 10, 2026USDCPI y/y●●●Forecast 4.2%Previous 3.7%
- November 10, 2026USDCore CPI m/m●●●Forecast 0.2%Previous 0.3%
- November 10, 2026USDCPI●●●Forecast 338.683Previous 336.298
- November 10, 2026USDCPI m/m●●●Forecast 0.5%Previous 0.6%
- November 10, 2026USDCore CPI n.s.a. m/m●●●Previous 0.4%
- November 10, 2026USDCore CPI●●●Forecast 339.796Previous 338.896
Coming up
- TomorrowUSDInitial Jobless Claims●●●in 1 day
- TomorrowUSDEIA Crude Oil Stocks Change●●●in 1 day
- November 13, 2026USDCore PPI m/m●●●Forecast 0.4%Previous 0.7%in 2 days
- November 13, 2026USDPPI m/m●●●Forecast 0.4%Previous 1.3%in 2 days
- November 17, 2026USDRetail Sales m/m●●●Forecast 0.3%Previous 0.8%in 6 days
- November 17, 2026USDCore Retail Sales m/m●●●Forecast 0.7%Previous 0.9%in 6 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
Both worlds over time
Technical and news signals of the last 90 days on one timeline.
What is being reported about AMGN
In-depth analysis of Amgen
AI-generated · as of November 5, 2026
Amgen screens strongly bullish across short, mid and long horizons, and the reason is a fundamental story that has turned. With no fresh technical signals in play, the verdict leans fully on the news flow, and that news flow has flipped from damaging to constructive.
Read full analysis
The damage came in early September, when Novartis reported disappointing late-stage results for pelacarsen, its lipoprotein(a) cardiovascular drug. Investors extrapolated the failure to Amgen's rival program, olpasiran, and the shares plunged about 10% in two days, the worst performance in the Dow, the S&P 500 and the Nasdaq 100. At least eight bearish signals clustered in that week, but the pattern pointed to sector-wide biotech de-risking rather than an Amgen-specific miss. Since then the stock has stabilized, and on November 5 a real-world study of more than half a million adults with heart disease showed Repatha cut heart attack risk by 20% versus ezetimibe, a clear win for the PCSK9 franchise. Amgen is also being framed as a defensive holding with a growing pipeline and dividend, and it remains a top position in the PBE healthcare ETF, which anchors institutional demand. The tension worth watching: the Novartis read-through risk is not resolved until Amgen reports its own olpasiran data, so a binary catalyst still hangs over the recovery. High-impact US jobs and inflation releases in the coming days set the macro backdrop but carry no fixed direction for the shares.
Frequently asked questions about Amgen
Why did Amgen fall so sharply in September 2026?
On September 8-9 the shares dropped roughly 10% after Novartis reported disappointing late-stage results for pelacarsen, a lipoprotein(a) cardiovascular drug. Because Amgen runs its own Lp(a) program, olpasiran, investors applied the same efficacy and safety concerns to it. The selloff hit amid a broader biotech rotation following Novartis's third trial setback in a week, and Amgen ended up the worst performer in the Dow, the S&P 500 and the Nasdaq 100. Notably, nothing operational had gone wrong at Amgen itself.
What does the new Repatha study mean for the stock?
The study, released November 5, tracked over 500,000 adults with heart disease and found Repatha cut heart attack risk by 20% versus ezetimibe. That is a clear positive for the PCSK9 franchise and underpins the bullish shift in the news picture. The caveats: it is real-world evidence rather than a new pivotal trial, prescribers may weight randomized data more heavily, and the release included no sales guidance, so the financial impact depends on uptake and payer decisions.
What is the biggest remaining risk for Amgen?
The olpasiran readout. The September plunge was a read-through from Novartis's failure, and that uncertainty is not resolved until Amgen reports its own Lp(a) data. Until then the shares carry a binary catalyst: a good result could lift the stock meaningfully, while a repeat of Novartis's outcome would validate the September fears. On the market side, a break below the post-selloff base near the September lows would reopen the drawdown risk.
Could upcoming economic reports move Amgen shares?
Yes, though indirectly. Nonfarm payrolls and the unemployment rate are due within a day, and CPI figures follow in about four days, all high-impact releases. As a defensive, dividend-supported stock, Amgen can benefit when markets turn risk-off, but rate expectations shaped by these prints affect the whole equity market. They set the backdrop rather than a fixed direction for the shares, and company-specific items like olpasiran matter more.
📝 Overview Generated automatically
AMGN has been the subject of 17 signals across 17 articles in the last 365 days. Sentiment skews Bearish (76%).
Breakdown: 3 bullish, 13 bearish, 1 neutral.
Most-cited catalysts: European regulators' recommendation to withdraw Tavneos (1×), Data integrity probe findings (1×), Upcoming results from the Phase III OCEAN(a)-Outcomes study for olpasiran (1×). Most-cited risk factors: Amgen successfully appeals the decision or submits new data to overturn the withdrawal (1×), The EU withdrawal has limited financial impact if Tavneos sales are minimal (1×), Negative read-through from Novartis's failed pelacarsen trial regarding the efficacy of Lp(a) reduction (1×).
Related assets
Same category or comparable signal picture — each card opens the full cockpit.